A BioMarin Pharmaceutical drug met just one of two main goals of a Phase 3 test in a rare inherited enzyme deficiency with no FDA-approved therapies. The drug, a fusion protein, came from BioMarin’s 2025 acquisition of Inozyme Pharma.
The post BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug appeared first on MedCity News.
